Amniotic membrane patch shows promise for stubborn diabetic wounds

NCT ID NCT07116174

Recruiting now Disease control Sponsor: New Horizon Medical Solutions Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a weekly application of Xcell Amnio Matrix, a processed amniotic membrane, can help heal diabetic foot ulcers better than standard care alone. About 135 adults with diabetes and a foot ulcer that hasn't healed in 4 weeks to 1 year will take part. The main goal is to see if more wounds close completely within 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Xcell Amnio Matrix (a processed amniotic membrane allograft)
What this could lead to: If it works, this could offer a new option to help heal diabetic foot ulcers faster and more completely.
What could go wrong: This is an early-stage trial with only 135 participants, so results may not apply to everyone. The treatment is added to standard care, and its benefits beyond standard care are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC FOOT ULCER (DFU) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetic Foot

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC FOOT ULCER (DFU)

Contacts and locations

Locations

Limb Preservation Platform, Inc.
RECRUITING

Fresno, California, 93710, United States
North Park Podiatry
RECRUITING

San Diego, California, 92104, United States
Richard C. Galperin
RECRUITING

Dallas, Texas, 75208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.